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Background
Atherosclerotic intracranial arterial stenosis is an 
important cause of stroke that is increasingly being 
treated with percutaneous transluminal angioplasty and 
stenting (PTAS) to prevent recurrent stroke. However, 
PTAS has not been compared with medical management 
in a randomized trial.
Methods
Objective: To determine whether intracranial stenting 
(using the Wingspan self-expanding nitinol stent, Boston 
Scientiﬁ c) and intensive medical therapy is superior to 
intensive medical therapy alone for preventing stroke in 
recently symptomatic patients with severe intracranial 
atherosclerotic stenosis.
Design: Phase III, multi-center, randomized, open label, 
clinical trial.
Setting: 50 sites in the US
Subjects: Patients who had a recent transient ischemic 
attack or stroke attributed to stenosis of 70 to 99% of the 
diameter of a major intracranial artery.
Intervention: Eligible patients were randomized to receive 
either aggressive medical medical management alone or 
aggressive medical management plus PTAS with the use 
of the Wingspan stent system.
Outcomes: Th e primary end point was stroke or death 
within 30 days after enrollment or after a revascu lari-
zation procedure for the qualifying lesion during the 
follow-up period or stroke in the territory of the qualify-
ing artery beyond 30 days. Patients in the medical arm 
who undergo angioplasty for recurrent TIAs (i.e. cross-
overs) and who have a stroke or death within 30 days will 
also meet this endpoint.
Results
Of the 451 patients who underwent randomization, 227 
were assigned to the medical management group and 224 
to the PTAS group. Th e 30-day rate of stroke or death 
was 14.7% in the PTAS group (nonfatal stroke, 12.5%; 
fatal stroke, 2.2%) and 5.8% in the medical-management 
group (nonfatal stroke, 5.3%; non–stroke-related death, 
0.4%) (P  =  0.002). Beyond 30 days, stroke in the same 
territory occurred in 13 patients in each group. Th e 
probability of the occurrence of a primary end-point 
event over time diﬀ ered signiﬁ cantly between the two 
treatment groups (P  =  0.009), with 1-year rates of the 
primary end point of 20.0% in the PTAS group and 12.2% 
in the medical-management group.
Conclusions
In patients with intracranial arterial stenosis, aggressive 
medical management was superior to PTAS with the use 
of the Wingspan stent system, both because the risk of 
early stroke after PTAS was high and because the risk of 
stroke with aggressive medical therapy alone was lower 
than expected.
Commentary
Stroke is a major public health problem as it is a leading 
cause of death and long-term disability in the United 
States. Th ere are approximately 795,000 incident strokes 
each year, resulting in more than 140,000 deaths annually 
[1]. In 2010, the cost of stroke care was estimated at $74 
billion, with a mean lifetime cost of $140,000 per patient 
[2]. Atherosclerotic disease of the major intracranial 
arteries is a frequent cause of ischemic stroke with annual 
risk as high as 24% [3]. Patients with severe intracranial © 2010 BioMed Central Ltd
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arterial stenosis (70% to 99%) are at high risk of stroke in 
the territory of the stenotic artery [4], which is potentially 
amenable to intracranial angioplasty or stenting. 
Current primary prevention strategies include a combi-
nation of life style modiﬁ cation (smoking cessation, 
dietary intervention, weight loss, and exercise), anti-
hypertensive medications, antithrombotic therapy, and 
statins [5]. Recommended secondary prevention includes 
a combination of medical therapy and revascularization 
[6]. Tremendous advances have been made in cerebral 
revascularization techniques in recent years, which 
include percutaneous transluminal angioplasty (PTA) 
alone, PTA with stenting (PTAS) using balloon-mounted 
coronary stents, and extracranial-intracranial surgical 
bypass. However, unlike extracranial carotid disease, the 
long term eﬃ  cacy and safety of revascularization 
strategies of intracranial atherosclerotic disease have not 
been well established.
Several retrospective case series suggest that PTA alone 
is a safe and eﬀ ective treatment strategy for intracranial 
atherosclerotic disease [7]. However, PTA has several 
technical drawbacks including immediate elastic recoil of 
the artery and high restenosis rates [8]. Surgical bypass 
was shown to be inferior to medical therapy for middle 
cerebral artery stenosis [9]. While some studies reported 
that PTAS with balloon-mounted coronary stents was 
safe and eﬀ ective [10], others showed high rates of 
periprocedural morbidity (23%) and mortality (5%) [11].
Th e Wingspan, a ﬂ exible, self-expanding, is the ﬁ rst 
stent designed speciﬁ cally for the treatment of sympto-
matic intracranial atherosclerotic disease. Th e high 
ﬂ exibility of these stents makes them suitable for treat-
ment of lesions of the distal internal carotid artery and 
middle cerebral artery that are either inaccessible or 
diﬃ  cult to reach with a balloon-mounted coronary stent.
Th e Stenting and Aggressive Medical Management for 
Preventing Recurrent stroke in Intracranial Stenosis 
(SAMMPRIS) trial is the ﬁ rst prospective randomized 
trial in patients’ with symptomatic intracranial athero-
sclerotic disease to compare the Wingspan stent and 
aggressive medical therapy with aggressive medical 
therapy alone. Aggressive medical therapy included 
aspirin 325 mg per day for entire follow-up, clopidogrel 
75 mg per day for 90 days after enrollment, and aggressive 
risk factor management primarily targeting blood 
pressure <140/90  mmHg (<130/80 if diabetic) and LDL 
<70  mg/dl. However, the Data Safety Monitoring Board 
halted the trial  after enrollment of 451 (59%) of the 
planned 764 participants because of the signiﬁ cant stroke 
and mortality rates observed in the stent arm.
Th e SAMMPRIS is a well-conducted, multicenter, con-
trolled trial that has provided strong scientiﬁ c evidence 
of the superiority of medical therapy to PTAS. Th e two-
fold increased risk of stroke with stent clearly indicates 
that stenting should not be used for stroke prevention in 
high-risk individuals. Of particular concern is the 
signiﬁ cant number of periprocedural intracranial hemor-
rhages. Unlike coronary vasculature, intracranial vessels 
are more challenging to stent because they are diﬃ  cult to 
navigate due to their very tortuous course and sharp 
angles, and those vessels are delicate and more suscep-
tible to injury due to lack of supporting connective tissue.
Based on the current study, the authors recommend 
adding clopidogrel to aspirin for the ﬁ rst 90  days 
following stroke in patients with high grade intracranial 
stenosis. However, it has to be pointed out that the 
control arm does not represent the current standard of 
care for stroke prevention as addition of clopidogrel to 
aspirin has been shown to increase the risk of hemor-
rhage [12]. Th e main reason for adding clopidogrel to 
aspirin in the control arm of SAMMPRIS trial was to 
balance the antithrombotic regimen in order to establish 
the superiority of the stent. Th e study did not include an 
aspirin monotherapy arm to compare the result of aspirin 
monotherapy with dual antiplatelet (aspirin and clopido-
grel) therapy. Th erefore it is unclear whether a combi-
nation of aspirin and clopidogrel is superior to aspirin 
monotherapy, combination of aspirin and extended-
release dipyridamole, and clopidogrel monotherapy, all of 
which are acceptable options for secondary prevention 
after ischemic stroke or TIA [6].
Two ongoing trials, Vitesse Intracranial Stent Study for 
Ischemic Th erapy (VISSIT), which is comparing the use 
of the balloon-mounted stents to aspirin and clopidogrel, 
and Interventional Management of Stroke III (IMS III) 
trial, which is evaluating diﬀ erent revascularization 
strate gies including clot retrieval devices, should 
hopefully provide more insight towards optimal strategy 
for stroke prevention.
Recommendation
Treatment with the Wingspan stent system for patients 
with intracranial stenosis carries substantial risk of death 
and stroke and should be abandoned.
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